Earnings ·
Precision BioSciences reports Q3 net loss of $7.6M, or $(0.28) per share
DTILPrecision Biosciences Inc
Precision BioSciences reported a net loss of $7.6 million, or $(0.28) per share, for the quarter ended September 30, 2026, compared to a net loss of $21.8 million in the prior year period. The improvement was primarily driven by a non-cash gain of $12.8 million from changes in the fair value of warrant liabilities. Operating expenses totaled $20.4 million, with research and development costs decreasing slightly to $12.7 million as pre-IND studies concluded, partially offset by increased clinical trial costs for the ELIMINATE-B program. The company reported no revenue and ended the quarter with a cash balance of $108 million, which management expects will fund operations through 2028. Key operational milestones included dosing the first patient in the FUNCTION-DMD study and advancing the ELIMINATE-B trial for chronic hepatitis B. Precision BioSciences is a clinical-stage gene editing company developing therapies using its proprietary ARCUS platform.